Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer

Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer

Background: Clinically-available biomarkers to identify the fraction of patients with small cell lung cancer (SCLC) who respond to immune-checkpoint inhibitors (ICIs) are lacking. High nonsynonymous tumor mutational burden (TMB), as assessed by whole exome sequencing, correlates with improved clinic...

Full description

Bibliographic Details
Main Authors: Ricciuti, Biagio (Author), Kravets, Sasha (Author), Dahlberg, Suzanne E. (Author), Umeton, Renato (Author), Albayrak, Adem (Author), Subegdjo, Safiya J. (Author), Johnson, Bruce E. (Author), Nishino, Mizuki (Author), Sholl, Lynette M. (Author), Awad, Mark M. (Author)
Other Authors: Massachusetts Institute of Technology. Computational and Systems Biology Program (Contributor)
Format: Article
Language:English
Published: BMJ, 2020-11-24T22:06:18Z.
Subjects:
Article
Online Access:Get fulltext

Internet

Get fulltext

Similar Items